Efalizumab (Raptiva) for Treatment of Psoriasis - Two Corrections

The Medical Letter on Drugs and Therapeutics

FROM
ISSUE

1174

January 19, 2004

View Complete Issue Table of Contents 2019

Efalizumab (Raptiva) for Treatment of Psoriasis - Two Corrections

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2004 Jan 19;46(1174):7-8

Disclosures

Objective(s)

SUMMARY: Two Corrections: In the issue of December 8, 2003, volume 45, on page 97 in the table, infliximab (Remicade) is given at weeks 0, 2 and 6 (not days). On page 98, patients in the Leonardi study were treated with etanercept 50 mg twice a week, not once.

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.